Andy Chen
Stock Analyst at Wolfe Research
(3.73)
# 749
Out of 4,976 analysts
40
Total ratings
55.56%
Success rate
8.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $455.03 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $24.75 | - | 2 | Aug 4, 2025 | |
| VRNA Verona Pharma | Initiates: Outperform | $170 | $106.30 | +59.92% | 1 | Jul 1, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $54.29 | -9.74% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $17.60 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $48.05 | +14.46% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $61.12 | -0.20% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $11.84 | +77.36% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $22.19 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $35.14 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.57 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $15.80 | +26.58% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $21.52 | -11.69% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $16.37 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $768.00 | -9.24% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $86.56 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $23.40 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $43.26 | +50.25% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $44.57 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $453.80 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.79 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $13.42 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $61.00 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $54.10 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $12.91 | +31.68% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $395.25 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $146.68 | -71.37% | 1 | Feb 15, 2024 |
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $455.03
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $24.75
Upside: -
Verona Pharma
Jul 1, 2025
Initiates: Outperform
Price Target: $170
Current: $106.30
Upside: +59.92%
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $54.29
Upside: -9.74%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $17.60
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $48.05
Upside: +14.46%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $61.12
Upside: -0.20%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $11.84
Upside: +77.36%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $22.19
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $35.14
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $8.57
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $15.80
Upside: +26.58%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $21.52
Upside: -11.69%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $16.37
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $768.00
Upside: -9.24%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $86.56
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $23.40
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $43.26
Upside: +50.25%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $44.57
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $453.80
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $19.79
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $13.42
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $61.00
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $54.10
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $12.91
Upside: +31.68%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $395.25
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $146.68
Upside: -71.37%